Linden HM - Search Results

1

Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC).

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM. Peterson LM, et al. Among authors: linden hm. Mol Imaging Biol. 2019 Feb;21(1):191. doi: 10.1007/s11307-018-1287-7. Mol Imaging Biol. 2019. PMID: 30324461

2

Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.

Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, Lawton TJ, Linden HM, Livingston RB. Mankoff DA, et al. Among authors: linden hm. J Nucl Med. 2003 Nov;44(11):1806-14. J Nucl Med. 2003. PMID: 14602864 Free article.

3

Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer.

Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, Lindsley S, Austin-Seymour M, Livingston R. Eubank WB, et al. AJR Am J Roentgenol. 2004 Aug;183(2):479-86. doi: 10.2214/ajr.183.2.1830479. AJR Am J Roentgenol. 2004. PMID: 15269044

4

Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival.

Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Lawton TJ, Barlow WE, Schubert EK, Mankoff DA. Dunnwald LK, et al. Among authors: linden hm. Cancer. 2005 Feb 15;103(4):680-8. doi: 10.1002/cncr.20831. Cancer. 2005. PMID: 15637688 Free article.

5

Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.

Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, Petra PH, Peterson LM, Schubert EK, Dunnwald LK, Krohn KA, Mankoff DA. Linden HM, et al. J Clin Oncol. 2006 Jun 20;24(18):2793-9. doi: 10.1200/JCO.2005.04.3810. Epub 2006 May 8. J Clin Oncol. 2006. PMID: 16682724

6

Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?

Linden HM, Krohn KA, Livingston RB, Mankoff DA. Linden HM, et al. Clin Cancer Res. 2006 Oct 1;12(19):5608-10. doi: 10.1158/1078-0432.CCR-06-1152. Clin Cancer Res. 2006. PMID: 17020961 No abstract available.

7

Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).

Specht JM, Tam SL, Kurland BF, Gralow JR, Livingston RB, Linden HM, Ellis GK, Schubert EK, Dunnwald LK, Mankoff DA. Specht JM, et al. Among authors: linden hm. Breast Cancer Res Treat. 2007 Sep;105(1):87-94. doi: 10.1007/s10549-006-9435-1. Epub 2007 Feb 1. Breast Cancer Res Treat. 2007. PMID: 17268819

8

18F-Fluoroestradiol.

Sundararajan L, Linden HM, Link JM, Krohn KA, Mankoff DA. Sundararajan L, et al. Among authors: linden hm. Semin Nucl Med. 2007 Nov;37(6):470-6. doi: 10.1053/j.semnuclmed.2007.08.003. Semin Nucl Med. 2007. PMID: 17920354 Review.

9

Challenges in clinical studies with multiple imaging probes.

Krohn KA, O'Sullivan F, Crowley J, Eary JF, Linden HM, Link JM, Mankoff DA, Muzi M, Rajendran JG, Spence AM, Swanson KR. Krohn KA, et al. Among authors: linden hm. Nucl Med Biol. 2007 Oct;34(7):879-85. doi: 10.1016/j.nucmedbio.2007.07.014. Nucl Med Biol. 2007. PMID: 17921038 Free PMC article. Review.

10

Tumor receptor imaging.

Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA. Mankoff DA, et al. Among authors: linden hm. J Nucl Med. 2008 Jun;49 Suppl 2:149S-63S. doi: 10.2967/jnumed.107.045963. J Nucl Med. 2008. PMID: 18523071 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

114 results

Search Page